natgillin/translations-raw huggingface dataset:
The method according to claim 8, wherein the asthma is selected from the group consisting of allergic and non-allergic asthma. 
Primjena sukladno zahtjevu 8, naznačeno time, da je alergijska i nealergijska bolest dišnih puteva odabran od kronične opstruktivne bolesti pluća i astme.
The immunoconjugate of claim 4, wherein the IgG1 molecule comprises in its Fc domain one or more amino acid mutations that reduce the binding affinity of the immunoconjugate to an FcγRIIIa, FcγRI or FcγRIIa receptor. 
Imunokonjugat iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačen time, da navedena Fc domena obuhvaća jednu ili više mutacija aminokiselina, koja(e) smanjuje(u) vezanje Fc domene na Fc receptor, naročito Fcγ receptor.
a tract inlet (51, 71) for receiving exhaust gas ejected from the group of cylinders to which the exhaust tract (5, 7) is connectable, 
ulazni otvor kraka (51, 71) za prihvaćanje ispušnog plina izbačenog iz skupine cilindara na koje se može spojiti ispušni krak (5, 7); i
common connection aperture (91) closed and right and left exhaust tract aperture fully closed. 
priključak ili zajednički otvor za spajanje (91) je zatvoren i desni i lijevi otvor ispušnog kraka su potpuno zatvoreni.
The arrester according to claim 1, characterized in that the insulating body (1) is shaped as a bar, a strip or a cylinder. 
Gromobran u skladu s patentnim zahtjevom 1, naznačen time što izolirajuće tijelo (1) ima oblik šipke, trake ili valjka.
The arrester according to claim 1, characterized in that the insulating body (1) has an increased thickness in zones where the discharge chambers (5) open to the surface of the insulating body (1). 
Gromobran u skladu s patentnim zahtjevom 1, naznačen time što izolirajuće tijelo (1) ima povećanu debljinu u područjima gdje su lučne komore (5) otvorene prema površini izolirajućeg tijela (1).
The arrester according to claim 14, characterized in that the insulating body (1) includes a hollow component, wherein the additional electrode (7) is placed inside the hollow component. 
Gromobran u skladu s patentnim zahtjevom 14, naznačen time što izolirajuće tijelo (1) uključuje šuplju komponentu, gdje se dodatna elektroda (7) nalazi unutar šuplje komponente.
a heterologous polypeptide comprising at least 3 HPV antigens, each HPV antigen originating from a different HPV type; and 
heterolognog polipeptida koji sadrži najmanje 3 HPV antigena E7, gdje svaki HPV antigen potječe iz različitog tipa HPV-a; i
a protein comprising or consisting of, from N-terminal to C-terminal, (a) a fragment consisting of residues 1 to 183 of SEQ ID NO:2, 4 or 6, (b) a heterologous polypeptide comprising at least 3 HPV antigens, each HPV antigen originating from a different HPV type; and (c) a fragment consisting of residues 387 to 1706 of SEQ ID NO:2, 4 or 6; 
protein koji se sastoji od, od N-kraja do C-kraja, (a) fragmenta koji se sastoji od ostataka 1 do 183 u SEQ ID NO:2, 4 ili 6, (b) heterolognog polipeptida koji sadrži najmanje 3 HPV antigena E7, gdje svaki HPV antigen potječe iz različitog tipa HPV-a; i (c) fragmenta koji se sastoji od ostataka 387 do 1706 u SEQ ID NO:2, 4 ili 6;
a protein comprising or consisting of, from N-terminal to C-terminal, (a) a fragment consisting of residues 1 to 183 of SEQ ID NO:8, (b) a heterologous polypeptide comprising at least 3 HPV antigens, each HPV antigen originating from a different HPV type; and (c) a fragment consisting of residues 321 to 1705 of SEQ ID NO:8. 
protein koji se sastoji od, od N-kraja do C-kraja, (a) fragmenta koji se sastoji od ostataka 1 do 183 u SEQ ID NO:8, (b) heterolognog polipeptida koji sadrži najmanje 3 HPV antigena E7, gdje svaki HPV antigen potječe iz različitog tipa HPV-a; i (c) fragmenta koji se sastoji od ostataka 321 do 1705 u SEQ ID NO:8.
a protein comprising or consisting of, from N-terminal to C-terminal, (a) a fragment consisting of residues 1 to 183 of SEQ ID NO:2, 4 or 6, (b) a heterologous polypeptide comprising at least 3 HPV antigens, each HPV antigen originating from a different HPV type; and (c) a fragment consisting of residues 321 to 1706 of SEQ ID NO:2, 4 or 6; and 
protein koji se sastoji od, od N-kraja do C-kraja, (a) fragmenta koji se sastoji od ostataka 1 do 183 u SEQ ID NO:2, 4 ili 6, (b) heterolognog polipeptida koji sadrži najmanje 3 HPV antigena E7, gdje svaki HPV antigen potječe iz različitog tipa HPV-a; i (c) fragmenta koji se sastoji od ostataka 321 do 1706 u SEQ ID NO:2, 4 ili 6; i
the polypeptide has a solubility of at least 20 mg/mL, preferably 50 mg/mL or more, more preferably 90 mg/mL, as determined by the PEG exclusion method or by a concentration experiment; 
polipeptid ima topljivost od najmanje 20 mg/mL, poželjno 50 mg/mL ili više, poželjnije 90 mg/mL ili više ili 120 mg/mL ili više, najpoželjnije 150 mg/mL ili više, ili čak 200 mg/mL ili više, kako je određeno PEG postupkom isključivanja ili pokusom koncentracije;
less than 10% of the polypeptide forms pyroglutamate at the N-terminal glutamic acid during storage at a temperature of 37±5°C up to at least 2 weeks (preferably at least 3 weeks, at least 5 weeks, at least 8 weeks, at least 10 weeks, at least 3 months, at least 6 months, at least 1 year, 1.5 year or even 2 years or more), the % of pyroglutamate as measured by RP-HPLC; 
manje od 10% polipeptida tvori piroglutamat na N-terminalnom kraju glutaminske kiseline tijekom skladištenja na temperaturi od 37±5°C do najmanje 2 tjedna (po mogućnosti najmanje 3 tjedna, najmanje 5 tjedana, najmanje 8 tjedana, najmanje 10 tjedana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više), te se % piroglutamata mjeri pomoću RP-HPLC;
less than 10% of the polypeptide forms dimers during storage at a temperature of 37±5°C up to at least 2 weeks (preferably at least 3 weeks, at least 5 weeks, at least 8 weeks, at least 10 weeks, at least 3 months, at least 6 months, at least 1 year, 1.5 year or even 2 years or more), the % of dimers as measured by SE-HPLC; 
manje od 10% polipeptida tvori dimere tijekom skladištenja na temperaturi od 37±5°C do najmanje 2 tjedna (poželjno najmanje 3 tjedna, najmanje 5 tjedana, najmanje 8 tjedana, najmanje 10 tjedana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više), te se % dimera mjeri pomoću SE-HPLC;
at least 80% of the polypeptides retains their binding activity to at least one of their targets after storage at 37±5°C up to at least 2 weeks (preferably at least 3 weeks, at least 5 weeks, at least 2 months, at least 6 months, at least 1 year, 1.5 year or even 2 years or more) compared to the binding activity prior to storage, said binding activity as measured by ELISA and/or Biacore; and/or 
najmanje 80% polipeptida zadržava svoju aktivnost vezanja na barem jedan od svojih ciljeva nakon skladištenja na temperaturi od 37±5°C do najmanje 2 tjedna (poželjno najmanje 3 tjedna, najmanje 5 tjedana, najmanje 2 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više) u usporedbi s aktivnošću vezanja prije skladištenja, navedena aktivnost vezanja izmjerena je pomoću testa ELISA i/ili testa Biacore; i/ili
A pharmaceutical unit dosage form suitable for parenteral administration to a human, comprising a formulation according to any of claims 1 to 13 in a suitable container. 
Farmaceutski jedinični oblik doziranja pogodan za parenteralnu primjenu kod čovjeka, naznačen time što sadrži formulaciju prema bilo kojem od zahtjeva 1 do 15 u pogodnom spremniku.
analysing in vitro the response to the specific pharmacological chaperone in a host cell that has been transformed with a nucleic acid vector that encodes a first mutant a-Gal A by a method comprising: 
analiziranje in vitro odgovora na specifični farmaceutski šaperon u stanici domaćina koja je transformirana vektorom nukleinske kiseline koji kodira prvi mutant a-Gal A pomoću postupka koji sadrži:
determining whether the first mutant a-Gal A is responsive to treatment with the specific pharmacological chaperone; 
određivanje da li prvi mutant a-Gal A odgovara na liječenje sa specifičnim farmaceutskim šaperonom;
compiling a table listing responsive and non-responsive mutant forms of a-Gal A, wherein the specific pharmacological chaperone is 1-deoxygalactonojirimycin or a pharmaceutically salt or ester thereof; the first and second host cells are HEK-293 MSR cells; and a mutant a-Gal A is defined as responsive to treatment with the pharmacological chaperone if: there is a 1.3 to 40-fold increase in a-Gal A activity in the first host cells compared with the a-Gal A activity in the second host cells; or 
sastavljanje tablice s popisom odgovarajućih i ne-odgovarajućih mutiranih oblika a-Gal A, pri čemu je specifični farmaceutski šaperon 1-deoksigalaktonojirimicin ili njegova farmaceutska sol ili ester; prve i druge stanice domaćina su stanice HEK-293 MSR; i mutant a-Gal A se definira kao odgovarajući za liječenje s farmaceutskim šaperonom ako: postoji 1.3 do 40-struko povećanje aktivnosti a-Gal A u prvim stanicama domaćina u usporedbi s aktivnošću a-Gal A u drugim stanicama domaćina; ili aktivnost a-Gal A u prvim stanicama domaćina je najmanje oko 2 do 100% aktivnosti a-Gal A od stanica HEK-293 MSR koje izražavaju divlji tip a-Gal A.
A peptide consisting of the sequence LTFGDVVAV (SEQ ID No. 10). 
Peptid koji se sastoji od sekvence aminokiselina prema SEQ ID br. 10.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 5.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 4. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 5.
A method according to claim 1 or 2, characterized in that the first and second segments of the rim portion (5) are successive segments and bent relative to each other to a substantially right angle, and that the first and second segments of the folding portion (7) are successive segments and bent relative to each other to an angle of more than 90°and less than 180°. 
Postupak prema zahtjevu 1 ili 2, naznačen time da su prvi i drugi segmenti rubnog dijela (5) uzastopni segmenti i međusobno su savijeni uglavnom pod pravim kutem, te da su prvi i drugi segmenti preklopnog dijela (7) uzastopni segmenti i međusobno su savijeni pod kutem većim od 90 ° i manjim od 180 °.
is H, F, Cl, —CN, OCH3, OCHF2, OCF3, cyclopropyl, or C(1-4)alkyl; wherein said C(1-4)alkyl is optionally substituted with up to five fluorine atoms, and said cyclopropyl is optionally substituted with OH, CH3, CF3, —CN, and up to five fluorine atoms; or R1 and R2 may be taken together with their attached ring A to form a fused ring system selected from the group consisting of naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl, wherein said naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl are optionally substituted with F, CHF2, CH2F, CF3, or CH3; provided that R2 may not be H if R1 is H; 
je H, F, Cl, -CN, OCH3, OCHF2, OCF3, ciklopropil, ili C(1-4)alkil; pri čemu navedeni C(1-4)alkil je proizvoljno supstituiran s do pet fluorovih atoma, i navedeni ciklopropil je proizvoljno supstituiran s OH, CH3, CF3, -CN, i do pet fluorovih atoma; ili R1 i R2 mogu biti uzeti zajedno s njihovim prstenom A za koji su vezani tako da tvore spojeni prstenasti sustav odabran iz skupine koju čine naftalenil, izokinolinil, tetrahidronaftalenil, i kinolinil, pri čemu su navedeni naftalenil, izokinolinil, tetrahidronaftalenil, i kinolinil proizvoljno supstituirani s F, CHF2, CH2F, CF3, ili CH3; pod uvjetom da R2 ne može biti H ukoliko R1 je H;
The pharmaceutical composition for use according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one. 
Farmaceutski pripravak za uporabu prema zahtjevu 1 naznačen time što farmaceutski pripravak sadrži oko 1 do 4 mg (11β,17β)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona.
The pharmaceutical composition for use according to claim 1 to 2 wherein the pharmaceutical composition comprises about 2 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra4,9-dien-3-one. 
Farmaceutski pripravak za uporabu prema zahtjevu 1 do 2 naznačen time što farmaceutski pripravak sadrži oko 2 mg (11β,17β)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra4,9-dien-3-ona.
The pharmaceutical composition for use according to claim 1, 2 or 3 comprising additionally a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za uporabu prema zahtjevu 1, 2 ili 3 naznačen time što dodatno sadrži farmaceutski prihvatljiv nosač.
The pharmaceutical composition or use according to claims 1 to 4 in a form of an oral dosage, wherein the dosage form is a tablet or a capsule. 
Farmaceutski pripravak ili uporaba prema zahtjevima 1 do 4 u obliku oralnog doziranja, naznačen time što je oblik doziranja tableta ili kapsula.
The pharmaceutical composition according to claims 1 to 5 for use in the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds. 
Farmaceutski pripravak prema zahtjevima 1 do 5 za uporabu za liječenje i/ili profilaksu ginekološke bolesti koja je poželjno naznačena time što obuhvaća pretjerano krvarenje iz maternice, kao što su fibroidi maternice (miomi, leiomiom maternice), endometrioza ili pretjerana menstrualna krvarenja.
The oral dosage form according to claim 8 or 9 for the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds. 
Oralni oblik doziranja prema zahtjevu 8 ili 9 za liječenje i/ili profilaksu ginekološke bolesti koja je poželjno naznačena time što obuhvaća pretjerano krvarenje iz maternice, kao što su fibroidi maternice (miomi, leiomiom maternice), endometrioza ili pretjerana menstrualna krvarenja.
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of preparing a mixture of phospholipid, antioxidant agent and alcohol (122) wherein 0.7-0.75 g dipalmitoylphosphatidylcholine (DPPC) and 0.05-0.1 g resveratrol are mixed into 350 mL alcohol and they are dissolved. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku pripravljanja smjese fosfolipida, antioksidacijskog sredstva i alkohola (122), gdje se 0,7-0,75 g dipalmitoilfosfatidilkolina (DPPC) i 0,05-0,1 g rezveratrola pomiješa u 350 ml alkohola, te ih se otopi.
A dermal matrix production method (10) according to claim 1, characterized in that said aqueous solution is added into the alcohol mixture and mixed (123) at 40 ± 1° C. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se navedenu vodenu otopinu dodaje u alkoholnu smjesu, te miješa (123) na 40 ± 1° C.
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of preparing collagen solution (111) by adding bovine collagen at a concentration of 0.1% to the 0.1 M acetic acid. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku pripravljanja otopine kolagena (111) dodavanjem goveđeg kolagena u koncentraciji u 0,1 % 0,1 M octene kiseline.
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of adding laminin onto the collagen solution (112) by taking 2.5ml of the collagen solution that has been prepared, adding 20 µl laminin into this, and mixing them in an ice bath. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku dodavanja laminina u otopinu kolagena (112) uzimanjem 2,5 ml pripravljene otopine kolagena, dodavanju tome 20 ml laminina, te njihovom miješanju u ledenoj kupelji.
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of freezing and storing the mixture (113} wherein the collagen and laminin mixture is left to wait for 12 hours overnight at a temperature of -20 ± 1 °C. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku smrzavanja i spremanja smjese (113), gdje se smjesu kolagena i laminina ostavi stajati 12 sati preko noći na temperaturi od –20 ± 1 °C.
A dermal matrix production method (10) according to claim 1, characterized in that it comprises the step of lyophilisation of the mixture (114) that has been stored, wherein the mixture which has been frozen and left to wait is subjected to lyophilisation for 24 hours and as a result wherein the deterioration of the biomaterials sensitive to heat, present inside said mixture is prevented. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku liofiliziranja spremljene smjese (114), gdje se smjesu koja je smrznuta i ostavljena stajati podvrgava liofiliziranju u trajanju od 24 sata, čime se postiže sprječavanje propadanja biomaterijala osjetljivih na toplinu, prisutnih u navedenoj smjesi.
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of cross linking lyophilisate (115), wherein the lyophilisate structure is subjected to cross linking under 254 nm wavelength using an ultraviolet cross linker (UV-cross linker) device. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku umrežavanja liofilizata (115), gdje se strukturu liofilizata podvrgava umrežavanju kod valne duljine od 254 nm uz upotrebu uređaja za ultraljubičasto umrežavanje (UV-umrežavanje).
A dermal matrix production method (10) according to claim 1, characterized by comprising the step of preparing an aqueous solution of polymer (121) wherein 0.2 g hyaluronic acid (HA) is dissolved in 150 mL pure water. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku pripravljanja vodene otopine polimera (121), gdje se 0,2 g hijaluronske kiseline (HA) otapa u 150 ml čiste vode.
A weighted exercise apparatus according to claim 2 or 3 comprising at least two locking pins provided at circumferentially spaced locations around the handle. 
Opterećena sprava za vježbanje u skladu sa zahtjevom 2 ili 3, sadržeći barem dva klina za zaključavanje predviđena na obodno razmaknutim mjestima oko ručke.
A weighted exercise apparatus according to claim 4 wherein the at least two locking pins are longitudinally aligned and located at diametrically opposed positions. 
Opterećena sprava za vježbanje u skladu sa zahtjevom 4, naznačena time da su barem dva klina za zaključavanje uzdužno poravnata i smještena na dijametralno suprotnim pozicijama.
A weighted exercise apparatus according to claim 5 wherein the actuating member comprises at least two diametrically opposed sprung pins operatively connected to the at least two locking pins at common circumferential positions arranged such that inward compression of the actuating pins causes simultaneous inward retraction on the locking pins. 
Opterećena sprava za vježbanje u skladu sa zahtjevom 5, naznačena time da se pogonski član sastoji od barem dva dijametralno suprotna klina s oprugama, operativno povezana s barem dva klina za zaključavanje na zajedničkim obodnim pozicijama, raspoređena tako da kompresija pogonskih klinova prema unutra uzrokuje simultano povlačenje klinova za zaključavanje prema unutra.
A weighted exercise apparatus according to claim 8 wherein the strap is adjustable to vary the size of the loop to prevent removal of the inserted hand. 
Opterećena sprava za vježbanje u skladu sa zahtjevom 8, naznačena time da je traka podesiva za mijenjanje veličine karike radi sprječavanja micanja umetnute ruke.
the polypeptide has a solubility of at least 20 mg/mL, preferably 50 mg/mL or more, more preferably 90 mg/mL or more or 120 mg/mL or more, most preferably 150 mg/mL or more, or even 200 mg/mL or more, as determined by the PEG exclusion method or by a concentration experiment; 
polipeptid ima topljivost od najmanje 20 mg/mL, poželjno 50 mg/mL ili više, poželjnije 90 mg/mL ili više ili 120 mg/mL ili više, najpoželjnije 150 mg/mL ili više, ili čak 200 mg/mL ili više, kako je određeno PEG postupkom isključivanja ili pokusom koncentracije;
the polypeptide has a melting temperature of at least 59°C or more, preferably at least 60°C or more, more preferably at least 61°C or more or at least 62°C or more, most preferably at least 63°C or more as measured by the thermal shift assay (TSA) and/or differential scanning calorimetry (DSC); 
polipeptid ima temperaturu taljenja od najmanje 59°C ili više, poželjno najmanje 60°C ili više, poželjnije najmanje 61°C ili više ili najmanje 62°C ili više, najpoželjnije najmanje 63°C ili više mjereno pomoću testa toplinskog pomaka (TSA) i/ili pomoću diferencijalne pretražne kalorimetrije (DSC);
the polypeptide is stable during mechanical stress. 
polipeptid je stabilan tijekom mehaničkog naprezanja.
The formulation of claim 8, wherein the excipient is a saccharide, a non-reducing sugar and/or polyol. 
Formulacija prema zahtjevu 8, naznačena time što je pomoćna tvar saharid, nereducirajući šećer i/ili poliol.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 5.